What question did this study set out to answer?

This study aims to investigate the effects of lenalidomide on T cell function and its enhancement of Mosunetuzumab efficacy in follicular lymphoma.

December 8, 2025BloodOpen Access

Mosunetuzumab and lenalidomide combination therapy augments CD8+ T cells with enhanced T cell-dependent cytotoxicity against follicular lymphoma cells

View Full Paper

Ask AI

Bookmark

Authors

HMHayato MizutaKeio University KFKoh FurugakiASKA Pharmaceutical (Japan)

Discussion

Member takes

Implication

Combination therapy improves CD8+ T cell activity and increases pro-inflammatory cytokines in follicular lymphoma, suggesting a novel treatment strategy.

Key Points

This study aims to investigate the effects of lenalidomide on T cell function and its enhancement of Mosunetuzumab efficacy in follicular lymphoma.
T cells were isolated from human peripheral blood mononuclear cells and co-cultured with follicular lymphoma cell lines.
Mosunetuzumab and lenalidomide treatments were applied in different combinations to analyze cytotoxicity.
Flow cytometry was used to assess T cell characteristics and cytokine levels after 7 days of treatment.
The combination of Mosun + Len significantly enhanced cytotoxicity of CD8+ T cells against follicular lymphoma cell lines.
There was a marked increase in CD8+ T cell numbers and the expression of cytotoxic granules in the Mosun + Len group.
Higher levels of pro-inflammatory cytokines such as IL-2 were produced in the combination therapy compared to Mosun monotherapy.

Cite This Study

Mizuta et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d289 https://doi.org/10.1182/blood-2025-1806

View Full Paper

Ask AI

Bookmark

Implication

Combination therapy improves CD8+ T cell activity and increases pro-inflammatory cytokines in follicular lymphoma, suggesting a novel treatment strategy.

Mosunetuzumab and lenalidomide combination therapy augments CD8+ T cells with enhanced T cell-dependent cytotoxicity against follicular lymphoma cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Mosunetuzumab and lenalidomide combination therapy augments CD8+ T cells with enhanced T cell-dependent cytotoxicity against follicular lymphoma cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider